Equibles does not estimate personal net worth.
Get an email with a short summary when Guardant Health, Inc. publishes a filing, an earnings call transcript or a press release.
Get GH alertsAmirAli Talasaz is recorded as Board Member at Guardant Health, Inc. (GH) since January 1, 2013 and CEO at Guardant Health, Inc. (GH). The newest filing on record that lists AmirAli Talasaz as CEO and Board Member at Guardant Health, Inc. (GH) is dated April 28, 2026. The proxy statement of Guardant Health, Inc. reports total compensation of $26,415 for AmirAli Talasaz in fiscal 2023, including a base salary of $1. Disclosed compensation is on record for 7 fiscal years. AmirAli Talasaz has spoken on 21 earnings calls and 2 other investor events across 1 company, most recently for Guardant Health, Inc. on November 5, 2026. Guardant Health, Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at Guardant Health, Inc. includes Helmy Eltoukhy (CEO, Chairman and Board Member), Michael Bell (CFO), Ines Dahne-Steuber (COO) and 7 others.
“Moving to slide 17, before reviewing our screening results, I'd like to share a patient's story that illustrates the potential of the SHIELD platform. A man in his 60s was behind on his recommended cancer screenings.”
“Q2 was another fantastic quarter for Garden Health. The flywheel of gardens is moving, accelerating, and a bunch of stuff that we work on for a few years, they are all coming to result and contribution for gardens right now.”
“Yeah, we're very excited with what's happening on the SHIELD front, like we're in the second year of launch now. And, you know, it's really, I think we graduated from category building phase to really category scaling right now.”
“Moving on to slide 12, we developed SHIELD from the ground up as a multi-cancer detection platform. SHIELD is clinically validated for detection of 10 different cancer types and is approved by the FDA for colorectal cancer screening as its first indication.”
“Q1 was another strong quarter for S.H.I.E.L.D. We delivered $42 million of S.H.I.E.L.D. testing revenue driven by approximately 44,000 tests, compared to $6 million revenue and approximately 9,000 tests in Q1 of 2025.”
2013-01-01–present
Last confirmed April 28, 2026
Source not stated
Start not stated–present
Last confirmed April 28, 2026
Start not stated–2021-08-05
Diagnostics & Research · Healthcare
CEO, Board Member
2013-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Guardant Health, Inc. (GH) | Co-Chief Executive Officer | $1 | $26,415 |
| 2022 | Guardant Health, Inc. (GH) | Co-Chief Executive Officer | $1 | $11,175 |
| 2021 | Guardant Health, Inc. (GH) | Co-Chief Executive Officer | $1 | $13,271 |
| 2020 | Guardant Health, Inc. (GH) | Co-Chief Executive Officer | $209,937 | $113,885,040 |
| 2019 | Guardant Health, Inc. (GH) | Co-Chief Executive Officer | $500,000 | $914,906 |
| 2018 | Guardant Health, Inc. (GH) | President and Chief Operation Officer | $480,000 | $818,405 |
| 2017 | Guardant Health, Inc. (GH) | President and Chief Operation Officer | $460,000 | $4,136,113 |
